Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/18/2024 | $50.00 | Hold | Stifel |
| 9/3/2024 | $47.00 | Market Perform | Leerink Partners |
| 8/9/2024 | $68.00 | Buy | Deutsche Bank |
| 7/25/2024 | Outperform | William Blair | |
| 7/18/2024 | Buy → Hold | Needham | |
| 2/29/2024 | $85.00 → $55.00 | Overweight → Neutral | Piper Sandler |
| 1/23/2024 | $72.00 | Buy | Needham |
| 7/19/2023 | $79.00 | Outperform | Robert W. Baird |
William Blair analyst Margaret Andrew initiates coverage on Inari Medical (NASDAQ:NARI) with a Outperform rating.
n
Needham analyst Mike Matson downgrades Inari Medical (NASDAQ:NARI) from Buy to Hold.
4/A - Inari Medical, Inc. (0001531048) (Issuer)
4 - Inari Medical, Inc. (0001531048) (Issuer)
10-Q - Inari Medical, Inc. (0001531048) (Filer)
8-K - Inari Medical, Inc. (0001531048) (Filer)
144 - Inari Medical, Inc. (0001531048) (Subject)
SC 13G - Inari Medical, Inc. (0001531048) (Subject)
SC 13G/A - Inari Medical, Inc. (0001531048) (Subject)
SC 13G/A - Inari Medical, Inc. (0001531048) (Subject)
4 - Inari Medical, Inc. (0001531048) (Issuer)
4 - Inari Medical, Inc. (0001531048) (Issuer)
4 - Inari Medical, Inc. (0001531048) (Issuer)
IRVINE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its third quarter ended September 30, 2024. Third Quarter Financial and Recent Business Highlights Generated revenue of $153 million in Q3 of 2024, up 21% over the same quarter of last year.GAAP operating loss was $13.6 million in Q3 of 2024, compared to a $2.1 million operating income in the same quarter of last year.Non-GAAP operating loss was $0.4 million in Q3 of 2024, compared to a $4.8 million non-GAAP operating income in t
IRVINE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its third quarter 2024 financial results on Monday, October 28, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 844-825-9789 for domestic callers or 412-317-5180 for international callers. The live webinar may be acc
IRVINE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that Mitch Hill, Chief Financial Officer, will retire effective October 1, 2024 and will be succeeded by Kevin Strange, Inari's current SVP, Finance, Accounting, Strategy and Business Development. Mr. Hill has served as the CFO since 2019, and prior to that in various senior financial roles spanning over four decades. Mr. Strange joined Inari in 2020 as VP, Strategy and Business Development. Since 2023 he has served as the SVP, Finance, Accounting, Strate
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting
IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), today announced the appointment of Tim Benner as Senior Vice President of U.S. Sales and Dr. Andrew Niekamp as Vice President of Medical Affairs. Mr. Benner will be responsible for developing effective strategies across the company's multi-product sales platform and leading a high-performance commercial team to drive therapy penetration. Dr. Niekamp will be instrumental in advancing Inari's mission to improve patient care through physician education and new device development. "We are thrilled to welcome Tim to Inari. His extensive experience leading the commercial execution of disruptive healt
NEW YORK, March 25, 2024 /PRNewswire/ -- AppFolio Inc. (NASD:APPF) will replace Inari Medical Inc. (NASD:NARI) in the S&P MidCap 400, and Inari Medical will replace Callon Petroleum Co. (NYSE:CPE) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. S&P 500 constituent APA Corp. (NASD:APA) is acquiring Callon Petroleum in a transaction expected to be completed on or about that date pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector April 1, 2024 S&P MidCap 400 Addition AppFolio APPF Information Technology S&P
Stifel initiated coverage of Inari with a rating of Hold and set a new price target of $50.00
Leerink Partners initiated coverage of Inari with a rating of Market Perform and set a new price target of $47.00
Deutsche Bank initiated coverage of Inari with a rating of Buy and set a new price target of $68.00
IRVINE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced positive results from the prospective PEERLESS Randomized Controlled Trial (RCT) comparing FlowTriever to catheter-directed thrombolytics (CDT). The results were presented by Dr. Wissam Jaber, Professor of Medicine at Emory University School of Medicine and Co-Global Principal Investigator (PI), during the Late-Breaking Clinical Trial Session at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C. In reco
IRVINE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its third quarter ended September 30, 2024. Third Quarter Financial and Recent Business Highlights Generated revenue of $153 million in Q3 of 2024, up 21% over the same quarter of last year.GAAP operating loss was $13.6 million in Q3 of 2024, compared to a $2.1 million operating income in the same quarter of last year.Non-GAAP operating loss was $0.4 million in Q3 of 2024, compared to a $4.8 million non-GAAP operating income in t
ALISO VIEJO, Calif., Oct. 21, 2024 /PRNewswire/ -- Okami Medical today announced the closing of a $32.5M financing led by new investor Vensana Capital and joined by existing investors including U.S. Venture Partners, members of Okami's board of directors, and other medical device industry veterans. Okami was launched by medical device incubator Inceptus Medical, whose principals previously founded other category-defining vascular companies including Inari Medical, Sequent Medical, and MicroVention. The financing provides Okami with capital to accelerate development and commerc